Table 4.
Comparison of 2-year outcomes between MAC and RIC haplo-SCT according to disease status
| Disease | Patients group and p value | RI | NRM | LFS | OS | cGVHD |
|---|---|---|---|---|---|---|
| Diagnosis | AML | 36.1 % (31.6–40.6) | 31.6 % (27.4–35.9) | 32.2 % (27.7–36.7) | 37.7 % (33.1–42.4) | 29.2 % (24.8–33.7) |
| ALL | 40 % (32.5–47.3) | 32.9 % (28.6–37.2) | 27.2 % (20.2–34.1) | 33.3 % (25.9–40.7) | 29.8 % (22.8–37.2) | |
| p | 0.43 | 0.87 | 0.45 | 0.40 | 0.67 | |
| All patients | ||||||
| CR1 | RIC | 30.1 % (19.1–41.9) | 31.1 % (24.1–38.3) | 38.9 % (26.4–51.3) | 46.9 % (34.1–59.8) | 26 % (15–38.3) |
| MAC | 21.5 % (15.4–28.3) | 29.1 % (22.2–36.3) | 49.1 % (41.2–57.1) | 55.4 % (47.5–63.4) | 41 % (32.8–48.9) | |
| p | 0.21 | 0.80 | 0.42 | 0.64 | 0.10 | |
| ≥ CR2 | RIC | 38.5 % (25.8–51.1) | 36.8 % (28.2–45.5) | 24.6 % (13.1–36.1) | 29.8 % (17.7–41.9) | 29.6 % (17.5–42.8) |
| MAC | 30 % (21.5–39) | 27.8 % (19.7–36.4) | 42.2 % (32.6–51.7) | 47.7 % (38–57.5) | 37 % (27.4–46.6) | |
| p | 0.38 | 0.25 | 0.06 | 0.07 | 0.53 | |
| Active dis. | RIC | 55.8 % (45.9–64.6) | 32.9 % (24.5–41.5) | 11.3 % (5–17.5) | 14.3 % (7.3–21.3) | 21.4 % (13.8–30.1) |
| MAC | 51.9 % (42.3–60.6) | 37.1 % (28.6–45.7) | 11 % (4.7–17.2) | 18.5 % (11.2–25.7) | 15.2 % (9.2–22.7) | |
| P | 0.52 | 0.38 | 0.64 | 0.60 | 0.29 |
Active dis active disease, cGVHD chronic graft-versus-host disease, CR complete remission, LFS leukemia-free survival, NRM non-relapse mortality, MAC myeloablative conditioning, OS overall survival, RI relapse incidence, RIC reduced intensity conditioning